Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats.

De Gennaro-Colonna V, Rossoni G, Cocchi D, Rigamonti AE, Berti F, Muller EE

The Journal of endocrinology1 Sept 2000Cited by 16 (Europe PMC)

PMID10974647DOI10.1677/joe.0.1660529PepBankPUB-10974647

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In lean Zucker rats, an acute hexarelin injection raised plasma GH.
In plain wordsIn lean rats, a single hexarelin injection raised growth hormone in the blood.
Peptide
Hexarelin
Outcome
IncreasePlasma GH after acute hexarelin injection, lean rats
Study
ratn: not reported in source
obese and lean Zucker rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microgram · subcutaneous · acute injection on day 28As given in this study (rat).
Source sentences
Summary
An acute hexarelin injection (80 microgram, s.c.) at the 28th day of treatment elicited a rise in plasma GH levels in ! lean but not in obese rats
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464701
02AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, an acute hexarelin injection did not raise plasma GH, whether or not the rats were pretreated with hexarelin.
In plain wordsIn obese rats, a single hexarelin injection did not raise growth hormone in the blood.
Peptide
Hexarelin
Outcome
No significant changePlasma GH after acute hexarelin injection, obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microgram · subcutaneous · acute injection on day 28As given in this study (rat).
Source sentences
Summary
An acute hexarelin injection (80 microgram, s.c.) at the 28th day of treatment elicited a rise in plasma GH levels in ! lean but not in obese rats
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464702
03AnimalAnimal study (in vivo)Efficacy outcome
In lean Zucker rats, chronic hexarelin treatment gave a greater plasma GH increase than in control lean rats.
In plain wordsIn lean rats, 30 days of hexarelin led to a bigger growth hormone rise than in untreated lean rats.
Peptide
Hexarelin
Outcome
IncreasePlasma GH rise in lean rats chronically treated with hexarelin
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline-treated lean rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
lean rats chronically treated with hexarelin showed a greater increase in plasma GH as compared with control counterparts.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464703
04AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, hexarelin did not increase pituitary GH mRNA, which was reduced in obese rats.
In plain wordsIn obese rats, hexarelin did not raise growth hormone gene activity in the pituitary gland.
Peptide
Hexarelin
Outcome
No significant changePituitary GH mRNA in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
pituitary GH mRNA levels were significantly reduced in obese rats and hexarelin administration failed to increase pituitary GH mRNA and IGF-I concentrations in plasma and heart.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464704
05AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, hexarelin did not increase plasma IGF-I concentrations.
In plain wordsIn obese rats, hexarelin did not raise IGF-I in the blood.
Peptide
Hexarelin
Outcome
No significant changePlasma IGF-I in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
pituitary GH mRNA levels were significantly reduced in obese rats and hexarelin administration failed to increase pituitary GH mRNA and IGF-I concentrations in plasma and heart.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464705
06AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, hexarelin did not increase heart IGF-I concentrations.
In plain wordsIn obese rats, hexarelin did not raise IGF-I in the heart.
Peptide
Hexarelin
Outcome
No significant changeHeart IGF-I in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
pituitary GH mRNA levels were significantly reduced in obese rats and hexarelin administration failed to increase pituitary GH mRNA and IGF-I concentrations in plasma and heart.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464706
07AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, chronic hexarelin treatment increased insulinemia.
In plain wordsIn obese rats, 30 days of hexarelin raised insulin levels in the blood.
Peptide
Hexarelin
Outcome
IncreaseInsulinemia in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
Chronic treatment with hexarelin increased insulinemia and blood glucose levels in obese but not in lean rats
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464707
08AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, chronic hexarelin treatment increased blood glucose levels.
In plain wordsIn obese rats, 30 days of hexarelin raised blood sugar.
Peptide
Hexarelin
Outcome
IncreaseBlood glucose in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
Chronic treatment with hexarelin increased insulinemia and blood glucose levels in obese but not in lean rats
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464708
09AnimalAnimal study (in vivo)Efficacy outcome
In lean Zucker rats, chronic hexarelin treatment did not increase insulinemia.
In plain wordsIn lean rats, 30 days of hexarelin did not raise insulin levels.
Peptide
Hexarelin
Outcome
No significant changeInsulinemia in lean rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
Chronic treatment with hexarelin increased insulinemia and blood glucose levels in obese but not in lean rats
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464709
10AnimalAnimal study (in vivo)Efficacy outcome
In lean Zucker rats, chronic hexarelin treatment did not increase blood glucose levels.
In plain wordsIn lean rats, 30 days of hexarelin did not raise blood sugar.
Peptide
Hexarelin
Outcome
No significant changeBlood glucose in lean rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
Chronic treatment with hexarelin increased insulinemia and blood glucose levels in obese but not in lean rats
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464710
11AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, chronic hexarelin treatment left the high triglyceride levels unaltered.
In plain wordsIn obese rats, 30 days of hexarelin did not change the high triglyceride levels.
Peptide
Hexarelin
Outcome
No significant changeTriglycerides in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
left unaltered the high triglyceride levels
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464711
12AnimalAnimal study (in vivo)Efficacy outcome
In obese Zucker rats, chronic hexarelin treatment significantly decreased plasma cholesterol concentrations.
In plain wordsIn obese rats, 30 days of hexarelin lowered cholesterol in the blood.
Peptide
Hexarelin
Outcome
DecreasePlasma cholesterol in obese rats
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
but significantly decreased plasma cholesterol concentrations in obese rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464712
13AnimalAnimal study (in vivo)Efficacy outcome
In lean and obese Zucker rats, 30 days of hexarelin counteracted ischemic heart damage, with higher recovery of left ventricular developed pressure at reperfusion than in controls.
In plain wordsIn lean and obese rats, 30 days of hexarelin helped the heart recover pressure after reduced blood flow, compared with controls.
Peptide
Hexarelin
Outcome
IncreaseRecovery of left ventricular developed pressure after ischemia
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
Hexare! lin administration for 30 days counteracted the heart ischemic damage both in lean and obese Zucker rats. In fact, the recovery of LVDP at reperfusion was significantly higher than in controls and the increase in coronary resistance was minimal.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464713
14AnimalAnimal study (in vivo)Efficacy outcome
In lean and obese Zucker rats, 30 days of hexarelin kept the increase in coronary resistance after ischemia minimal.
In plain wordsIn lean and obese rats, 30 days of hexarelin limited the rise in heart vessel resistance after reduced blood flow.
Peptide
Hexarelin
Outcome
DecreaseCoronary resistance after ischemia and reperfusion
Study
ratn: not reported in source
obese and lean Zucker rats
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
80 microgram/kg b.i.d. · subcutaneous · 30 daysAs given in this study (rat).
Source sentences
Summary
Hexare! lin administration for 30 days counteracted the heart ischemic damage both in lean and obese Zucker rats. In fact, the recovery of LVDP at reperfusion was significantly higher than in controls and the increase in coronary resistance was minimal.
1 context sentence(design, population, supporting numbers)
Summary · context
Obese and lean male rats of the Zucker strain were treated with hexarelin (80 microgram/kg, b.i.d., s.c.) or saline (1 ml/kg, b.i.d., s.c.) for 30 days.
Report a problemFND-1097464714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.